PTIX
Protagenic Therapeutics, Inc.\newCompany Information
- Company Name
- Protagenic Therapeutics, Inc.\new
- CIK
- CIK0001022899
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- PTIX: OTC
- Fiscal Year End
- March 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- PTIX
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-08-21
- Last sale
- —
- Shares purchased (TTM)
- 73,530
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 41,806
- Shares outstanding
- 1,810,208
- Ownership
- 2.31%
Earnings Market Reaction
- Filing date
- 2026-08-19
- Price on filing date
- —
- 1-month reaction
- 148.86%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | |||||||||||||||||
| Cash | 1 | 2 | 2 | 3 | 1 | 2 | 1 | 1 | 1 | 1 | 0 | ||||||
| Marketable Securities Current | - | - | - | - | - | - | - | - | 2 | 3 | 5 | ||||||
| Prepaid Expense Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Value Added Tax Receivable Current | - | - | 0 | 0 | - | - | - | - | - | - | - | ||||||
| Inventory Net | - | - | 0 | 0 | - | - | - | - | - | - | - | ||||||
| Assets Current | 1 | 2 | 2 | 3 | 1 | 2 | 1 | 1 | 2 | 4 | 5 | ||||||
Assets Noncurrent | |||||||||||||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Intangible Assets Net Excluding Goodwill | 2 | 2 | 2 | 2 | - | - | - | - | - | - | - | ||||||
Liabilities And Stockholders Equity | |||||||||||||||||
| Assets Noncurrent | 2 | 2 | 2 | 2 | - | - | - | - | - | - | - | ||||||
| Assets | 3 | 4 | 4 | 5 | 1 | 2 | 2 | 1 | 3 | 4 | 5 | ||||||
Liabilities Current | |||||||||||||||||
| Notes Payable Current | - | - | 3 | 3 | - | - | - | - | - | - | - | ||||||
| Accounts Payable Current | 1 | 1 | 2 | 2 | - | - | - | - | - | - | - | ||||||
| Accrued Liabilities Current | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | ||||||
| Derivative Liabilities Current | - | - | 1 | 4 | - | - | - | - | - | - | - | ||||||
| Loans Payable Current | - | - | 1 | 1 | - | - | - | - | - | - | - | ||||||
| Liabilities Current | 1 | 1 | 7 | 10 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | ||||||
| Liabilities | 1 | 1 | 7 | 10 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | ||||||
Stockholders Equity | |||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 7 | 7 | 7 | 7 | 38 | 37 | 36 | 35 | 35 | 35 | 34 | ||||||
| Retained Earnings Accumulated Deficit | -5 | -4 | -9 | -11 | -38 | -36 | -35 | -34 | -33 | -31 | -29 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | - | - | - | - | -0 | -0 | -0 | -0 | -0 | -0 | -1 | ||||||
| Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax | -0 | -0 | -0 | -0 | - | - | - | - | - | - | - | ||||||
| Stockholders Equity | 2 | 3 | -2 | -5 | -0 | 1 | -2 | 1 | 2 | 4 | 4 | ||||||
| Liabilities And Stockholders Equity | 3 | 4 | 4 | 5 | 1 | 2 | 2 | 1 | 3 | 4 | 5 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 2 | 2 | 2 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | ||||||
| Common Stock Shares Issued | 2 | 2 | 2 | 2 | 1 | 7 | 5 | 4 | 4 | 4 | 4 | ||||||
| Shares Outstanding | 2 | 2 | 2 | 2 | 1 | 7 | 5 | 4 | 4 | 4 | 4 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialProtagenic Therapeutics, Inc.\new (PTIX) — SEC Financial Statements & Analysis
Protagenic Therapeutics, Inc.\new (PTIX) is a pharmaceutical preparations company, incorporated in DE. Protagenic Therapeutics, Inc.\new trades on OTC as: PTIX. Protagenic Therapeutics, Inc.\new (PTIX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-19. Based on that filing, Protagenic Therapeutics, Inc.\new carries a market cap of $709.60K, a P/E ratio of 1.88x, a P/B ratio of 0.41x, an enterprise value of $143.62K, and an EV/EBITDA multiple of -0.05x. On profitability, it posts a Return on Equity (ROE) of 46.19%, a Return on Assets (ROA) of 19.96%, and a Return on Invested Capital (ROIC) of -3059.60%. Per share, it reports EPS of $0.21, diluted EPS of $0.21, free cash flow per share of $-1.63, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -107.21% year-over-year and EPS growth of -102.08% year-over-year. On the balance sheet, it maintains a current ratio of 0.66x, a quick ratio of 0.53x, working capital of $-362.74K, a debt-to-equity ratio of 0.62x, a debt ratio of 0.38, an interest coverage ratio of -43.52x, free cash flow of $-2.95M (TTM), and net debt of $-565.99K. Figures sourced from SEC EDGAR.
- Market Cap
- $709.60K
- P/E TTM
- 1.88x
- EPS TTM
- $0.21
- P/B TTM
- 0.41x
- ROE TTM
- 46.19%
- ROA TTM
- 19.96%
- Debt To Equity
- 0.62x
- Free Cash Flow TTM
- $-2.95M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Protagenic Therapeutics, Inc.\new in?
Protagenic Therapeutics, Inc.\new (PTIX) operates in the Pharmaceutical Preparations industry.
What exchange does PTIX trade on?
Protagenic Therapeutics, Inc.\new (PTIX) trades on the OTC.
Where is Protagenic Therapeutics, Inc.\new incorporated?
Protagenic Therapeutics, Inc.\new is incorporated in DE.
When was Protagenic Therapeutics, Inc.\new (PTIX)'s most recent SEC filing?
Protagenic Therapeutics, Inc.\new (PTIX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-19.
What is PTIX's market cap?
Protagenic Therapeutics, Inc.\new (PTIX) has a market capitalization of $709.60K as of 2026-06-30.
What is PTIX's P/E ratio?
Protagenic Therapeutics, Inc.\new (PTIX)'s trailing twelve month P/E ratio is 1.88x as of 2026-06-30.
What is PTIX's EPS (earnings per share)?
Protagenic Therapeutics, Inc.\new (PTIX)'s trailing twelve month EPS is $0.21 as of 2026-06-30.
What is PTIX's ROE (return on equity)?
Protagenic Therapeutics, Inc.\new (PTIX)'s trailing twelve month Return on Equity (ROE) is 46.19% as of 2026-06-30.
What is PTIX's ROA (return on assets)?
Protagenic Therapeutics, Inc.\new (PTIX)'s trailing twelve month Return on Assets (ROA) is 19.96% as of 2026-06-30.
What is PTIX's ROIC (return on invested capital)?
Protagenic Therapeutics, Inc.\new (PTIX)'s trailing twelve month Return on Invested Capital (ROIC) is -3059.60% as of 2026-06-30.
What is PTIX's EV/EBITDA?
Protagenic Therapeutics, Inc.\new (PTIX)'s trailing twelve month EV/EBITDA is -0.05x as of 2026-06-30.